Sandoz joins Accord in targeting US university
Managing IP is part of the Delinian Group, Delinian Limited, 4 Bouverie Street, London, EC4Y 8AX, Registered in England & Wales, Company number 00954730
Copyright © Delinian Limited and its affiliated companies 2024

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Sandoz joins Accord in targeting US university

Viersen, Germany - May 9. 2020: Close up of mobile phone screen

The claim, filed this week against the University of California’s governing board, follows action by Accord Healthcare in October

Sandoz has become the second pharmaceutical company in the last few months to take action against the governing board of the University of California, according to a case filed with the England and Wales High Court on Tuesday, January 24.

The generics arm of Swiss outfit Novartis has filed pleadings against The Regents of the University of California. Publicly available documents are expected to be released in early February.

Sandoz filed the case in the patents division of the England and Wales High Court, but no further details are available at this stage.

The case follows action taken by Accord Healthcare in October last year in which the pharma company sought to invalidate a European patent and supplementary protection certificate (SPC) owned by the Regents.

That dispute arose after Accord signalled its intention to produce a capsule form of enzalutamide, a treatment for prostate cancer, in 2024 following the expiry of market exclusivity.

In the Accord case, the Regents first claimed that launching a capsule before the expiry date of a patent (EP 1,893,196) and SPC (GB13/079) it owns would amount to infringement.

In a counterclaim, Accord sought an order that the patent, called ‘diarylhydantoin compound’, is invalid and that the SPC is also invalid and should not come into force.

That case is expected to go to trial in the coming months. It is not known at this stage if the Sandoz dispute surrounds the same claims.

Bristows is representing Sandoz, whereas the Regents’ counsel have not been announced yet. In the Accord case, Pinsent Masons is acting for Accord while the Regents is being represented by Kirkland & Ellis.

more from across site and ros bottom lb

More from across our site

The UPC judges are wrong – restricting access to court documents, and making parties appoint a lawyer only to have a chance of seeing them, is madness
The group, which includes the Volkswagen, Seat and Audi brands, is now licensed to use SEPs owned by more than 60 patent owners
Managing IP’s Max Walters appeared on the latest episode of ‘Two IPs in a pod’, a regular podcast hosted by the UK patent attorney body, to discuss AI, awards and more
Sources at law firms say they have spent more than three years waiting for IP regulations and explain how the delay is affecting their business
We provide a rundown of Managing IP’s news and analysis coverage from the week, and review what’s been happening elsewhere in IP
Managing IP will host a ceremony in London on April 11 to reveal the winners of the EMEA Awards 2024
Lawyers reveal what trends they have noticed in the Western District of Texas and the advice they have been giving clients as a result
Concerns over the EU’s proposed SEP Regulation are based on little empirical support, say Benno Buehler and Kilian Mueller of Charles River Associates
Managing IP+ has launched the Talent Tracker, an interactive database that collates reported partner moves across the intellectual property legal market
With the boom in UPC work, the biggest challenge facing the Munich-based firm is recruitment
Gift this article